

SUBJECT INDEX

A

ABA systems
and T_s cell interactions, 140

Acetylated proteins
macrophage as receptor for, 297

Acetylcholine receptors
and isolated membrane systems studies, 261

Acquired immunodeficiency syndrome
see AIDS

Actin
and macrophage activation, 289

Acumentin
and macrophage cytoskeletal apparatus, 289

Acute lymphoblastic leukemia (ALL)
and IL-2 receptor system studies, 329

ADCC
activation for, 306-07
functional competence for, 312

Adenocarcinoma
and ganglioside, 114

Adenylate cyclase
as a chemoattractant receptor, 265

Adrenergic receptors
hormone interactions, 264
and isolated membrane systems studies, 261

Adult T-cell leukemia (ATL)
and IL-2 receptor system, 330-31
and T-cell defects, 320

Aerobic glycolysis
and macrophage activation, 289

Agonists
chemoattractant receptor affinity by, 266-67

AIDS
and T-cell defects, 320

Aliphatic alcohols
lipid composition in leukocyte membranes, 268

Allergic reactions
platelet involvement in, 5

Alloantigens
and marrow transplantation, 225
and T-cell activation, 37

Allogenic bone marrow transplants
model for mutual tolerance, 233

Allografts
of adult pancreatic islets, 185-91
fetal pancreas, 191-93

Allosteric proteins
and antigenicity, 91

Amino acid
antigenic structure of protein, 90

Aminoglycoside antibiotic G418
and transfection of immunoglobulins, 243

Anaphylatoxin activity
and C5a chemoattractant, 258

Anaphylaxis
biomedical research, 5
in the rabbit, 12

Anti-B2 microglobulin
and IgE responder strains, 163

Antibiotics
historical footnote, 4-5

Antibodies
anticonotypic
screening strategy, 33
antigen molecules
and radioactive suicide, 13
antilymphocyte
and histamine, 12
antireceptor
and disulfide-bonded heterodimers, 57-60
and MHC specificity, 56-57
and peptides, 60-63
and target T cells, 54-56
bactericidal, 480-81
binding
clonal effector population, 27
chemically synthesized peptides, 68
clone-specific
and antigen receptors, 52-54
clonotypic
and T-cell receptor studies, 63
donor-specific anti-Ia, 187-88
hemagglutinating
and induction of unresponsiveness, 213

IgE
and X irradiation, 159

monoclonal
see Monoclonal antibodies
polyclonal
and lysozyme, 77

sepharose-bound
and T-cell clones, 39
T cells as activators, 55-56
T3 molecular complex antigens, 30-31
see also IgE synthesis

Antibody dependent cellular cytotoxicity
see ADCC

Antibody specificity
and small peptides, 74
Antigen-antibody complex
formation
and vascular permeability, 343

Antigen foreignness
and antibody response, 89

Antigenicity
tumor-associated carbohydrates, 118-20

Antigen immunization
and T_s cells, 140

Antigen nonspecific suppression
and immunoregulation, 127

Antigen processing
and macrophage cells, 395-409

Antigen receptors
and clone specific antibodies, 52-54
see also MHC-restricted antigen receptors

Antigen recognition
lymphocytes
(table), 46
by T-cells
model of, 45-47

Antigens
Au
and Down's syndrome, 18
blood group
in human cancer, 116-18
blood group A-like
and cancer, 105
C isotype switching, 507, 510-17
class I
and human islet transplants, 188
class I MHC antigens, 26
D
and islet transportation, 190

- deaggregated
and selective induction,
129-30
- Forssman
in human cancer, 105
- ganglio-series
in human cancers, 109
- globo-series
and human cancer, 110
- glycolipid
crypticity of, 119
defined by monoclonal anti-
bodies, 109-14
- Hepatitis B
and blood transfusions, 17-
18
- histocompatibility
and evidence for clonal de-
letion, 221
and islet allografts, 187
- Ia
induction of and lympho-
kines, 287
and islet allografts, 187
and nonphagocytic func-
tions, 295-96
- inactivation of clones, 221
- MAC-1
and suppressor cells, 228
- MHC
and T-cells, 75
and mitogens
and C isotype switching,
497-538
- oncofetal, 109
- polyoma T
and cell transfection, 249
- protein
multideterminant-regulatory
model, 89-94
- SV40 T
transfection of immunoglo-
bulins, 241
- surface T3
and CTL effector function,
32
- and T lymphocytes, 23
- T-cell
surface expression of, 35-36
- T-dependent
and C isotype switching,
517-35
and IgE antibody response,
159
and immunoregulation, 127
- T3 molecular complex
and antibodies, 30
- T (Thomsen-Friedenreich)
and panagglutination, 115
- transplantation
and protein structure, 67-95
- tumor-associated
glycolipid, 108-14
- see also
Carbohydrate antigens,
tumor-associated
- Cytochrome
Lysosome
Macrophage, Antigen-
presenting function of
Myoglobin
Serum albumin
- Antigen-specific regulation
of the IgE response, 160-61
- Antigen-specific suppressor T
cells
see Suppressor cells and im-
munoregulation
- Antihapten responses
antibody formation, 160
inhibition of
and polysaccharides, 13-14
- Anti-I-J serum
and immunologic unrespon-
siveness, 189
- Antineoplastic function
and macrophage activation,
310-11
- Antisera
cytochrome c, 80
early investigations, 2, 5
high-titer
and synthetic peptides, 74
identification of constant-
peptide regions with, 62
- polyclonal
quantitative micro-
complement fixation
technique, 90
- T-cell hybridomas, 52
- Antistreptolysin S
and plasma lipoproteins, 5
- Anti-T3 antibody-induced mod-
ulation
and antigen-specific human T-
cell clones, 31-33
- Antitumor effects
of activated macrophage, 283
- Arachidonate
and leukocyte protein kinase
C, 275
- Arachidonic acid metabolites
and macrophage activation,
300
- Arachidonic acid oxygenation
products
role of in pain and inflamma-
tion
effects of on lymphocyte
function, 348-51
effects of on phagocytic cell
function, 345-48
enzymes and products of,
336-39
introduction, 335-36
mediators of fever, 341-42
- mediators of pain, 339-41
regulators of blood flow/
vascular permeability,
342-45
- Aristotelian examination
as method of hypothesis, 9
- Arteriosclerosis
and diabetes mellitus, 183
- Arthritis
adjuvant
PGE 1, 343
effect of mycobacteria on,
209
inflammatory
and C5a, 258
relation to collagen autoim-
mune, 207-09
see also Collagen autoimmune
arthritis
- Rheumatoid arthritis
- Arthus reaction
biomedical research, 5
platelets and granulocytes in,
11-12
- Aspirin
antiserum to, 2
as cyclooxygenase inhibitor,
351
- Atopic dermatitis
IgE-specific potentiating fac-
tor, 178
- Au antigen
and Down's syndrome, 18
- Australia antigen
see Hepatitis B
- B
- Baconian examination
as method of hypothesis, 8
- Bacteria
gram negative, 470-71
gram positive, 468-70
see also Complement and bac-
teria
- B cells
and antigens
as a trigger, 13
C_H isotype switching, 495
clones
and cytochrome c, 81
determinants in natural pro-
teins presented to, 396
enhancer-like sequences
and transfection of im-
munoglobulins, 255
- idiotypes
T cell-suppressor functions,
147-48
- IgE-bearing
and binding, 164
- immature
and clonal inactivation, 234

- and lymphoid irradiation, 225
- and memory
 - in cell generation, 14-15
- responses to cytochrome c polymer, 83
- responses to hapten-specific T suppression of, 131
- Biology
 - cellular
 - see Macrophage activation, cell biology of
- Blindness
 - and diabetes mellitus, 183
- Blood group antigens
 - in human cancer, 116-18
- Blood group substances
 - pseudomucinous cysts of ovary, 10-11
- Blood transfusions
 - for leukemia, 18
- B lymphocytes
 - as antibody-secreting plasma cells, 240
 - and IgE antibody, 170
 - immunoglobulin specificity, 248
 - and MHC, 51
 - neonatal tissue, 220
 - see also C_h isotype 'switching' during normal B lymphocyte development
- Bone marrow
 - and monocyte lineage
 - NK cells, 382
- Bone marrow transplants
 - model for mutual tolerance, 233
- BP treatment
 - and IgE-potentiating factor, 165-66
- Bradykinin
 - and pain mediation, 339
- Brain tumor
 - and peripheral blood B-lymphocytes, 110
- Breast cancer
 - and peripheral blood B-lymphocytes, 110
- Bronchial asthma
 - and eosinophils, 429
- C
 - $C5a$ chemoattractant receptors
 - anaphylatoxic activity, 258
 - and endotoxin treatment, 270-71
 - Cancer
 - antigen
 - "A" human, 114
 - blood group antigens in, 116-18
 - and Forssman glycolipid, 110-12
 - See also Acute lymphoblastic leukemia (ALL)
 - Adenocarcinoma
 - Adult T-cell leukemia (ATL)
 - Brain tumors
 - Breast cancer
 - Carbohydrate antigens
 - tumor-associated
 - Lymphoma
 - Melanoma
 - $C5b-9$
 - bacterial killing, 479
 - Candida
 - and macrophage activation capacities, 309
 - $CaPO_4$ precipitation
 - and cell transfection, 243-44
 - Carbohydrate antigens
 - tumor-associated
 - biochemical features of carbohydrate changes in tumors, 104-08
 - conclusions and perspectives, 120-21
 - factors affecting antigenicity and immunogenicity of tumor-associated carbohydrates, 118-21
 - glycolipid tumor-associated antigens, 108-14
 - glycoprotein tumor-associated antigens, 114-16
 - introduction, 103-04
 - modification of blood group antigens in cancer, 116-18
 - Carbohydrate moieties
 - in IgE-binding factors, 166-67
 - Carbohydrates
 - chains
 - high and low density organization, 118-20
 - components
 - and T-cell interaction, 324-25
 - uniqueness of structures in tumor cells, 119-20
 - Cationic peptides
 - and macrophage activation capacities, 309
 - Cell biology
 - see Macrophage activation, cell biology of
 - Cell cycle progression
 - regulation of
 - and IL-2 receptor, 328
 - Ceramide composition
 - crypticity of glycolipid antigens, 119
 - Charcot-Leyden Crystal Protein (CLC)
 - and eosinophil functions, 440-42
 - Chemoattractant-receptor signal biochemical transduction of, 273-76
 - Chemoattractant receptors on phagocytic cells
 - biochemical transduction, 273-76
 - $C5a$ chemoattractant receptors, 270-71
 - cellular-derived chemotactic factors, 272
 - introduction, 257
 - leukocyte chemoattractant receptor, 259-72
 - lipid chemotactic factors, 271-72
 - N-formulated opiopeptide receptor, 260-70
 - summary, 276-77
 - Chemoattractants
 - interaction of with leukocytes, 258
 - Chemotaxis
 - arachidonic acid metabolites, 345
 - cellular-derived factors and surface receptors, 272-73
 - desensitization of, 267
 - formylated peptides, 297-98
 - monocyte
 - methylation reaction of, 274
 - Chloramphenicol acetyltransferase (CAT) gene
 - bacterial
 - transcription of, 251
 - Cholesterol synthesis
 - and chemotaxis, 269
 - Chondritis
 - collagen-induced, 206
 - Chromatography
 - affinity
 - and N-formylated peptide receptor, 263
 - and peptide binding, 73
 - C_h isotype 'switching'
 - during normal B lymphocyte development
 - accompanying responses to Type 2 antigens, 510-17
 - apparent restriction in isotype potential in B cells, 517-35
 - conclusions, 538-40
 - introduction, 493-97

- and isotype potential, 494-95
- polyclonal stimulation with thymus-independent mitogens, 499-507
- responses to submitogenic doses of Type 1 antigens, 507-10
- restriction accompanying B-cell responses to mitogens/antigens, 497-538
- transition from Pre-B to B cells, 498-99
- unresolved issues, 535-38
- in vitro culture of single B-cell clones to assess B-cell responsiveness, 495-97
- Clonal deletion
 - and maintenance of neonatal tolerance, 221-22
- Clonal proliferation
 - CTL effector function, 41
 - induction of
 - by monoclonal antibodies, 39
- Clonal selection hypothesis
 - and monoclonal antibodies, 10
 - and radioactive suicide, 13
- Clones
 - isotype switching, 501-06
 - self-reacting
 - anergy of, 93
- Clonotypes
 - comparative analysis of (figure), 43
- Clonotypic surface structures
 - and antigen-specific human T-cell function, 33-34
- Collagen
 - autologous type II
 - effect of, 214
- Collagenase
 - and islet isografts, 184-85
 - and islet isolation, 194
 - as neutral protease, 299
- Collagen autoimmune arthritis
 - collagen arthritis in mice, 206-07
 - description of model, 200-01
 - extraarticular manifestations, 205-06
 - genetic control, 209-11
 - histologic changes, 201-03
 - in humans, 211-12
 - immunopathology, 203-05
 - induction of unresponsiveness, 213
 - introduction, 199
 - relationship to adjuvant arthritis, 207-09
 - summary, 213-14
- Collagen immunization
 - and polyarthritis, 200
- Complement and bacteria
 - chemistry and biology of host defense
 - bacterial antibody, 480-81
 - bacterial factors associated with serum resistance, 481-83
 - complement and opsonization, 463-68
 - complement system, 461-63
 - effects of opsonic antibody and C-reactive protein on complement activation by bacteria, 473-74
 - introduction, 461
 - involvement of complement in intracellular killing of bacteria, 476
 - mechanism of complement activation by bacteria, 468-73
 - mechanism of complement-mediated killing, 477-79
 - mechanism of resistance to complement-mediated killing, 483-85
 - nonantibody noncomplement factors required for complement killing, 481
 - role of complement in bacterial clearance from the blood stream, 474-76
- Computer programs
 - SCTFIT binding analysis, 261
- Concanavalin A
 - cloning of suppressor cells, 229
 - and T cell clones, 29
- Cosmic significance
 - and immunological discoveries, 8
- Critical examination
 - as method of hypothesis
 - see Galilean examination
- CTL
 - antigen specific
 - and B lymphoblasts, 29
 - cloned alloreactive
 - and monoclonal antibodies, 53
 - clones
 - and lectin approximation, 28
 - effector function
 - and anti-HLA antibodies, 29
 - strategy to clone, 24
- Cyclooxygenase products
 - and AAOP, 342
 - and mediators of pain, 339-41
- Cyclophosphamide
 - suppressor cell interactions, 137
- TS₃ cell factors, 138
- Cysts
 - see Ovary
- Cytochrome c
 - as an immunogen, 80-85
- Cytokine
 - production
 - and NK cell heterogeneity, 379-81
- Cytolysis
 - and T cell clones, 55
 - tumor
 - and macrophage functions, 303-06
- Cytolytic activity
 - of cloned cells
 - table, 38
 - competence
 - and macrophage capacities, 302
- Cytolytic cells
 - antigen-specific
 - and regulatory changes, 231
- Cytolytic T cell lymphocytes
 - and islet allografts, 187
 - precursors
 - reactivity of, 221
 - and suppressor cell interactions, 127-28
- Cytotoxic effector function
 - and activation of T cells, 23
- anti-HLA
 - influence of, 37
- anti-T3 modulation, 31
- and T4 subset, 24
- tumor specific cells, 36-37
- Cytotoxic effector lymphocytes
 - see CTL
- Cytotoxic T cell clones
 - NK cell heterogeneity, 377
 - target recognition by, 28
 - tumor cells, 36-37
- Cytotoxicity
 - and NK cell heterogeneity, 375
 - by T8+ cells, 24
 - and T4 clones, 27
- D
- DEAE-dextran
 - and cell transfection, 243-44
- Deaggregated antigen
 - and selective induction, 129
- Deductive examination
 - as method of hypothesis, 8-9

- Demonstrative examination
as method of hypothesis, 8-9
- Dendritic cells
follicular, 14
- Dermatitis
and IgE-specific potentiating factor, 178
- Diabetes mellitus
and pancreatic islets transplantation, 183
- Dihydroxyeicosatetraenoic acids
and lipoxygenase enzymes, 338
- Disulfide-bonded heterodimers
and antireceptor antibodies, 57-60
- DNA
cloned IL-2
and ATL, 331
clones
and T cells, 63
duplication
lymphocytes in, 319
encoding of RNA, 320
genetic code in, 8
human cancer, 108
immunoglobulin (Ig) molecule, 239
lymphocyte differentiation, 248
studies on control of receptors, 332
synthesis
IL-2 receptor, 327
suppressor-cell interactions, 147
transfection, 243
transient expression, 240
- DNP-Myc-primed cells
T cell hybridomas, 172
- Dopaminergic receptors
and hormone receptor interactions, 264
- Dose response curves
and bioassays, 5
- Down's syndrome
tendency to leukemia, 18
- Dysplasia
pre malignant
and A & B antigens, 116
- E
- Ear
lesions
and collagen arthritis, 206
- Edema
and AAOP, 336
as mediator, 342-45
- Effector functions
influence of anti-HLA on, 37
- Endocrine grafts
and induced rejection, 189
- Endocytosis
and macrophage activation, 310
- Endonuclease digestion
and cellular DNA, 322-23
- Environment
and histiocytes, 287
- Enzyme synthesis
and reactive oxygens, 301
- Eosinophil Cationic Proteins (ECP)
and eosinophil functions, 436-38
- Eosinophil-derived neurotoxin (EDN)
and eosinophil functions, 438-39
- Eosinophilic tetrapeptides
as chemoattractant, 258
- Eosinophil peroxidase (EPO)
and eosinophil functions, 434-36
- Eosinophils
and chemotactic activity, 346
immunobiology of, 429-52
eosinophil-associated proteins, 429-42
eosinophils and reproduction, 451-52
functions of eosinophils, 442-51
introduction, 429
- Erythema
and AAOP, 336
- Eukaryotic cells
cell studies, 328-29
and macrophage activation, 283
- Evolutionary studies
of albumin antisera, 88
- F
- Fc receptors
cell-surface capacities, 294
and MPS, 286
- Fever
and AAOP, 336
as mediator, 341
and muscle wasting, 302
- Fibronectin
and tumor specific carbohydrates, 104
- Formylated peptides
macrophage as receptor for, 297-98
- Forssman antigen
in human cancer, 105
- Forssman glycolipid
and cancer, 110
- G
- Galilean examination
as method of hypothesis, 9
- Gamma globulin
bovine
suppressor cell tolerance, 225
- Ganglioside
and human meconium, 114
- GAT system
plaque forming cell (PFC) responses, 130
- GEF
and biologic activities of IgE binding factor, 171
and T cell hybridoma, 175
- Gelsolin
and macrophage cytoskeletal apparatus, 289
- Genes
heavy chain
and immune response, 239
transfection
and myelomas, 244
- Genetics
control of immune responses, 16-17
encoding
and T-cell antigen receptor, 47
IL-2, 320-23
markers
dominant acting, 241
- Genome
and macrophage development, 313
- GIF
and biologic activities of IgE binding factors, 171
and IgE binding factors, 173
and N-linked oligosaccharide, 174
- Glomerulonephritis
and prostaglandins, 343
- Glucagon
hormone receptor interactions, 264
and islet isografts, 184
- Glucocorticoids
and IL-2 secretion, 330
- Glutathione
first synthesizer of, 2
- Glycolipids
carbohydrate changes in, 107
changes in, 106
crypticity of, 119
defined by monoclonal antibodies, 109-14
lacto-series
human tumor-associated antigens, 112
nomenclature of, 103

- role in cancer, 120-21
 shared antigens between, 115-16
 tumor associated, 104
 tumor-associated antigens, 108-14
Glycolysis
 and macrophage activation, 289
Glycopeptide fractions
 tumor associated, 106
Glycophorin
 and tumor specific carbohydrates, 104
Glycoproteins
 carbohydrate moieties of, 120
 changes in
 in human cancer, 106
 enzymatic basis of carbohydrate changes, 107
 and monoclonal antibodies, 34
 receptor
 and macrophage activation, 288
 shared antigens between, 115-16
 suppressor-cell interactions, 149
 T cell activation, 45
 T cell lineage-restricted surface, 24
 T cell lymphoma, 57
 tumor-associated antigens, 114
 virally encoded surface
 and class I molecules, 29
 20KD T3
 and T1 clonotype, 41
Glycosylation
 and carbohydrate structures, 107-08
 enhancing factor
 see GEF
 inhibiting factor
 see GIF
Gout
 arachidonic acid products, 348
 human PMNs, 272
Grants committees
 problems of innovation, 6-7
Granulocytes
 in Arthus reactions, 11-12
Guanine nucleotides
 N-formylated peptide receptor, 264-66

H
Haptened antigen presenting cells (APC)
 and suppressor cell interactions, 14

H-2 system
 genes
 suppressor T cell system, 128
 haplotype
 and suppressor cell interactions, 150
 in mice
 genetics studies, 15
Hearing loss
 and collagen arthritis, 206
Heart disease
 and strep infection, 4
HEL
 antigen presenting function of the macrophage, 407
 antigenic structure of, 75-80
 immune responses to, 78
 role of T cells with, 79
 see also Lysozyme
Helminth infection
 and eosinophils, 429, 442-45
Hemoglobin
 and allosteric proteins, 91
Hemagglutinin
 antigenic determinants of, 93
Hematopoiesis
 and role of suppressor cells, 228
Hemolytic system
 as a complement, 12
Hepatitis
 chronic anicteric, 18
Hepatitis B
 and blood transfusion, 17
Hepatocytes
 and kappa gene expression, 249
Herpes simplex
 and thymidine kinase genes, 241
Heterogeneity of natural killer cells
 conclusions, 383-84
 cytokine production and other noncytotoxic functions of LGL, 379-81
 general characteristics of NK cells, 363-73
 introduction, 359-62
 lineage of NK cells, 381-83
 regulation of NK activity, 378-79
 specificity of NK cells, 374-77
Hexapeptide
 and nonadherent human monocytes, 261
HGPT
 and nucleotide synthesis, 242
Histamine
 and blood flow, 344
 early hypothesis, 12
 as mediator of inflammation, 11
 as mediator of pain, 339
HLA
 nonpolymorphic
 and T cell clones, 26
Homeostatic mechanism
 and suppressor T cells, 127
Horror autotoxicus
 history of discovery, 2
HPETEs
 and lipoxygenase enzymes, 338
Human T cell receptor
 antigen like effects of monoclonal antibodies, 37-41
 clonotypic surface structures, 33-34
 conclusion, 47
 effects of monoclonal antibodies directed at monomorphous structures, 27-29
 functional effects from anti-T3 antibody-induced modulation, 31-33
 human cytotoxic T lymphocyte clones, 36-37
 introduction, 23-24
 model of antigen recognition, 45-47
 peptide variability within T1 molecules, 41-45
 quantification of surface expression of
 T cell antigens, 35-36
 T-cell subset derivation, 24-27
 T1: A 90KD disulfide-linked heterodimer, 41
 T1 & T3 in T cell membrane, 34-35
 T3 molecular complex, 30-31
Hybridoma
 and collagen arthritis, 207
 and T_S cells, 136
 T_S, 141
Hydroperoxyeicosatetraenoic acids
 see HPETEs
Hydrophobic effects
 and myoglobin, 70
Hyperalgesia
 and prostaglandins, 340
Hypersensitivity reactions
 eosinophil modulation of, 445-51
 and suppressor T-cell systems, 127
Hypoxanthineguanine phosphoribosyltransferase
 see HGPT

I

Ia expression
in cells other than macrophage, 417-19
and the macrophage, 414-17
Idiotypic-specific regulation and the IgE antibody response, 160

IgE
affinity for SFA and EFA, 169
antibody response and IgC response, 161
bearing B cells
binding factors, 164
binding factors and carbohydrate moieties, 166
cellular mechanisms for formation, 171
common antigen determinants in, 168
fractionation of, 170
glycosylation-inhibiting factor, 173
30K inactive, 169
mechanism for the formation of, 169
pharmacologic modulation of, 167
and polyinosinic-polycytidylic acid, 173
and T cells, 166
and B lymphocytes, 170
and FcR, 170
forming hybridoma and IgE synthesis, 163
hyper IgE syndrome and blood T cells, 178
isotype-specific regulation, 169
potentiating factor by antigenic stimulation, 171
and IgE suppressive factor, 168
and T cells, 173
receptor on mast cells, 273
response and binding factors, 165
and IgE potentiating factor, 166
specific regulatory factors properties of, 163
specific suppressive factor (IgE-TsF) and suppressor T cells, 162
suppressive factor by antigenic stimulation, 171
and MHC-barrier, 164

and T cell factors, 173

IgE synthesis
regulation of antigen-specific regulation of the response, 160-61
conclusion, 176-78
correlation between the IgE response and the nature of IgE binding factors, 165-66
formation of IgE-binding factors by specific ligand, 169-70
GEF, 175-76
GIF, 174-75
introduction, 159-60
isotype-specific T cells and regulatory factors, 161-65
mechanisms for the formation of binding factors, 169-73
relationship among regulatory factors, 166-69
T cell factors involved in potentiating factor, 173-76

IgE-TsF
and antigenic determinant, 162Ig genes
control regions in, 250
and transfection of immunoglobins, 240

Igh V
restrictions and molecular organization of TsF, 147-49

I-J homology
and induction of T cells, 133
restrictions, 144

IL-1
and mononuclear phagocytes as source of, 302

IL-2
NK cell heterogeneity, 383
receptor characterization of, 326-27
recombinant, 322
role of retrovirus, 331
and treatment with anti-T3, 32
see also Interleukin 2

Immune related molecules
non-Ig expression of, 249-50

Immune response
and induction of unresponsiveness, 213

Immunoaffinity purification of IL-2, 323

Immunocompetent cells and clonal selection theory, 219

Immunodeficiency diseases
functional responses of leukocytes, 270

Immunoferritin technique
and H-2 antigens
and islet allografts, 187

Immunofluorescence
and monoclonal antibodies, 24
and Ti clonotype, 41
and T3 molecular complex, 30

Immunogenicity
definition of, 68
of fetal allografts, 191
tumor associated carbohydrates, 118

Immunogens
antigen-specific clonal human T-cells, 23

Immunoglobulin
antigen binding, 45
and collagen autoimmune arthritis, 203
DNA clones, 63
discovery of, 6
expression tissue specificity of, 248-49
receptors and suppressor T cells, 128

Immunoglobulin genes
transfer and expression of conclusions and prospects, 253-54
control regions and Ig genes, 250-53
expression of immunoglobulin molecules, 245-48
expression of non-Ig immune related molecules, 249-50
introduction, 239-40
methods of transfecting cells, 243-44
tissue specificity of immunoglobulin expression, 239
vectors and transient vs. stable expression, 239

Immunohistochemical studies
and islet transplants, 184

Immunologic unresponsiveness and transplantation of pancreatic islets, 189

Immunopathology
and collagen autoimmune arthritis, 203-05

Immunoregulation
see Suppressor cells and immunoregulation

Immunoregulatory activities
and activation of T cells, 23

Immunosuppressive therapy
drugs, 195

- and islet transplants, 183
- Immunotherapy
 - experimental tumors, 120
- Indomethacin
 - and MLR suppressor cells, 224
 - and role of lymphocytes, 349
- Induction
 - and scientific thought, 8
- Inflammation
 - diseases of
 - and lymphocyte sensitivity, 349
 - immunologically mediated, 287
 - and macrophage, 284
 - see also Arachidonic acid oxygenation products
 - role of in pain and inflammation
- Inflammatory arthritis
 - and synovial effusions, 258
- Influenza virus
 - glycoproteins of, 93
- Insulin
 - and islet transplants, 195
- Interferon
 - and macrophage activation, 309
 - and mononuclear phagocytes as source, 302
 - and polyinosinic-poly-cytidylic acid (pI:pC), 173-74
- Interleukin 2
 - biologic relevance of receptor hormone system, 328-29
 - characterization of IL-2 receptor, 326-27
 - conclusion, 331-32
 - genetics, 320-23
 - immunologic relevance of receptor hormone system, 327-28
 - introduction, 319-20
 - mechanism of cell interaction, 325-26
 - monoclonal antibodies, 323-24
 - receptor system and T-cell malignancies, 329-31
 - structure, 324-25
 - see also IL-2
- Indomethacin treatment
 - and vascular permeability, 343
- Intuition
 - and discovery in science, 8
- Iodine
 - radioisotopes, 5
- Ir-genes
 - and IgE response, 159
- Irradiation, X-
 - and IgE antibody, 159
 - and IgE specific regulatory T cells, 162
- and suppressor-cell interactions, 137
- Islet allografts
 - recent research, 194
 - rejection of, 183
- Islet isografts
 - and transplantation, 184
- Islet transplants
 - and immunosuppressive drugs, 195-96
- Islet xenografts
 - and allograft rejection, 193
- J
- Joint destruction
 - and immune response, 199
- K
- Kallikrein
 - and GEF, 176
- Kantian examination
 - as method of hypothesis, 8
- Kappa light chain
 - and Ig genes, 250
 - and immunoglobulin molecules, 245
- L
- Lactoferrin
 - receptor for
 - on mononuclear phagocytes, 298
- Lapresle
 - human serum albumin studies, 85
- Large granular lymphocytes (LGL)
 - cloned, 380-81
 - and NK function, 363-68
- Lectin
 - approximation
 - and CTL clones, 28
 - as mitogens, 17
- Leishmania
 - and macrophage activation, 309
- Leukemia
 - chromosome study, 17
 - and Down's syndrome, 18
 - T cell
 - antireceptor antibodies, 62
 - IL-2 receptor system, 330
 - immunoprecipitates, 59-60
 - and monoclonal antibodies, 53
- Leukocyte
 - accumulation
 - and phagocytes, 257
 - chemoattractant receptors, 259-72
- chemotactic factors, 258
- chemotactic response
 - in vitro, 258
- cytotoxic properties of, 259
- infiltration
 - and AAOP, 347
- membranes
 - lipid composition in, 268
- passenger
 - and allografts, 186
- polymorphonuclear
 - and chemoattractant receptors, 276
- receptors
 - and lipid chemotactic factors, 271-72
- Leukotrienes
 - as inflammatory mediators, 335
- Lipids
 - chemotactic factors
 - and leukocyte receptors, 271-72
 - metabolism
 - and methylation reactions, 273-74
- Lipomodulin
 - and GIF, 174
 - and IgE, 167
- Lipopolysaccharide
 - see LPS
- Lipoproteins
 - receptor for, 297
- Lipoxygenase enzymes
 - and AAOP, 336
 - and pain, 341
 - and vascular permeability, 344-45
- LPS
 - and C₃ isotype switching, 499-507
 - and serum resistance, 481-83
- Lymph
 - thoracic duct
 - suppressor T cells, 221
- Lymphoid irradiation
 - tolerance induction, 224-25
 - see Natural suppressor (NS) cells, neonatal tolerance, and total lymphoid irradiation
- Lymph nodes
 - dendritic cells in, 191
- Lymphoblast
 - allogenic B
 - and T lymphocytes, 24
- Lymphocyte
 - and DNA duplication, 319
 - and inflammatory disease, 349
 - and islet xenografts, 193
 - proliferative responses, 200
- Lymphokine
 - and MPS, 286

- production
 - endogenous, 39
 - putative receptor for, 298
- secretion
 - and clonal proliferation, 42
- T cell hybridomas, 53
- Lymphoma
 - antigen
 - globo-series, 110
 - T cell
 - and glycoproteins, 57
 - transfection of immunoglobulins, 253
- Lysosome
 - formation of, 289
 - hydrolases, 298
- Lysozyme
 - c
 - and immune recognition, 75
 - and determinants for myoglobin, 92
 - and DNA, 244
 - enzyme secretion, 276
 - and macrophage activation, 299, 309
- M
- Macrocortin
 - and monoclonal antibodies, 175
- Macrophage
 - antigen-presenting function of
 - antigen presentation and Ia expression in other cells, 417-19
 - antigen processing, 395-409
 - introduction, 395
 - modulation of, 409-17
 - summary, 419-20
 - cytoskeletal apparatus
 - capacities of, 289
 - Macrophage activation
 - cell biology of
 - capacities vs. functions circuit/models, 284-86
 - conclusions and perspectives, 310-13
 - general development of mononuclear phagocyte system (MPS), 286-88
 - introduction, 283-84
 - macrophage capacities and regulation, 288-303
 - macrophage functions 303-10
- Major histocompatibility complex
 - restricted antigen receptor on T cells, 51-63
 - antireceptor antibodies are directed toward disulfide-bonded he-
- terodimers, 57-60
- antireceptor antibodies inhibit or stimulate function of target T cells, 54-56
- antireceptor antibodies predict T-cell antigen & MHC specificity, 56-57
- antireceptor antibodies recognize constant-variable peptide regions, 60-63
- clone-specific antibodies define the antigen receptors on MHC-restricted T cells, 52-54
- concluding remarks, 63-64
- introduction, 51-52
- see also MHC
- Mannose-fucose
 - receptor for
 - and macrophage activation, 295
- Marrow grafts
 - and tolerance induction, 224
- MBP
 - and eosinophil functions, 431-34
- Measles virus
 - infected Hela cells
 - and IgE binding factors, 174
- Methylation reactions
 - in chemoattractant receptor signal transduction, 273-74
- MHC
 - barrier
 - and IgE suppressive factor, 164
 - and B lymphocytes, 51
 - and collagen arthritis, 208
 - gene products
 - and T-cell receptors, 410
 - linked genes
 - and protein antigens, 93
 - model of immunoregulation, 149
 - restriction
 - of T-cell clones, 24-27
 - and rheumatic disease, 199
 - and suppressor T-cell system, 129
 - and T-cell receptor, 23
- Microbial destruction
 - activation for
 - and macrophage, 307-09
- Microbial diseases
 - and leukocytes, 257
- Mitochondrial respiration
 - and glycolysis, 289
- Mitogens
 - and C₃ isotype switching, 497-538
- Mitomycin C
 - and formation of IgE potentiating factor, 168
- Mixed leukocyte reaction (MLR)
 - and nonspecific suppressor cells, 219
- MLN cells
 - and IgE, 168
- MLR response
 - and cell transfection, 249
- Molecular biology
 - and C₃ isotype switching, 535-38
- Monoclonal antibodies
 - anti-clonotypic
 - influence on proliferative responses, 34
 - antigen like effects of, 37-41
 - anti-NP
 - and suppressor cell interactions, 138
 - anti-Ti and anti-T3, 40
 - BSA surface, 92
 - carbohydrate antigens, 104
 - for cloned lines of T cells, 53
 - hybridoma technology, 67
 - IgE binding factors, 168
 - and IL-2, 323-24
 - lectin, 29
 - noncrossreactive
 - clone-specific, 23
 - nonmorphic structures
 - antigen-specific function, 27-29
 - oncofet antigens, 109
 - poly-X haptens, 112
 - protein antigens, 68
 - quantitation of binding sites, 35
 - serum albumin, 87
- Monolayer adsorption techniques
 - and NK cell heterogeneity, 376-77
- Monomeric globular proteins
 - and antigenicity, 91
- Mononuclear phagocyte system (MPS)
 - general development of, 286-88
 - intracellular capacities, 289
- Motility
 - and N-formylated oligopeptide receptor, 267-70
- Multideterminant-regulatory model
 - and protein antigens, 89
- Muscarinic-cholinergic hormone receptor interactions, 264

- Mutagenesis
and immunoglobulin transfection, 240
- Myeloma
anti-TNP-specific
and transfection of immunoglobulins, 247
- Myoglobin
antigenic structure of, 69-75
determinants for, 92
evidence for topographic antigenic sites, 71
- Myosin
and macrophage cytoskeletal apparatus, 289
- N
- Natural suppressor (NS) cells
neonatal tolerance, and total lymphoid irradiation
ease of tolerance induction, 224-25
induction of tolerance in mice, 220-21
introduction, 219-220
in vitro culture and cloning of NS cells, 228-30
maintenance of neonatal tolerance, 221-22
naturally occurring suppressor cells, 226-28
relationship among NS cells, antigen-specific, 230-34
role of antigen specific suppressor cells, 226-28
summary, 234
- N-C terminal peptides
and antigenic structure of lysozyme, 76
immobilized
and HEL, 79
- N-formylated oligopeptide receptor
and agonist binding, 260
- Neonatal tolerance
clonal deletion, 221-22
induction of, 220-21
see Natural suppressor cells, and neonatal tolerance
- Neuraminidase treatment
and IgE suppressive activity, 167
- Nippostrongylus brasiliensis
and IgE antibody formation, 160
- N-linked oligosaccharide
and IgE response, 166
and GIF, 174
- Nobel prize
immunology winners, 1
- Nonlymphocytic antigen cells
and tolerance induction, 234
NP-specific cells
Ts₁ induction, 133
- O
- Ocular fluorophotometry
and islet transplant, 185
- Opsonin
systems
in serum, 461
- Opsonization
and serum factors, 463-68
- Ovalbumin
IgE antibody responses to, 161
- Ovary
pseudomucinous cysts
blood group substances, 10
- Oxazolone
and antigen-specific suppressor T cells, 146
- P
- Pain
see Arachidonic acid oxygenation products in pain and inflammation
- Panagglutination
and tumor-associated carbohydrates, 115
- Pancreatic islets
transplantation of
allografts of adult islets, 185-91
canine islet allografts, 194
fetal pancreas allografts, 191-93
human islet transplants, 195-96
induction of specific immunologic unresponsiveness, 189-90
intra-islet Ia positive cells, 191
introduction, 183
in vitro culture of megaislets in, 188
islet isografts, 184-85
islet xenografts, 193-94
pretreatment of islets with donor-specific anti-Ia antibody, 187-88
- PC-specific suppressive factor
and antigenic stimulation, 172
- Penicillin
and antibiotic discoveries, 5
procaine, 11
- Peptides
binding to myoglobin, 73
- chemoattractant receptors
on leukocytes, 263-64
as inhibitor
precipitation reactions, 70
mapping, 60-62
N-C terminal
and antigenic structure of lysozyme, 76
purified disulfide
and the Loop studies, 76
surface-simulated, 77
T-cell clones, 41-45
tryptic
maps of, 44
- Periostitis
and collagen induced arthritis, 201
- Peroxidase
and activity in eosinophils, 430
- PFC
response to GAT, 130
- Phagocytic cells
function
and effect of arachidonic acid metabolites, 345
see Chemoattractant receptors on—
- Phagocytosis (PHG)
as a function, 285
and microtubules, 289
receptors involved in, 294
and resident peritoneal macrophage, 309-10
- Phospholipases
and AAOP, 336
- Phosphorylation
and carbohydrate structures, 107
- Picryl
and antigen-specific suppressor T cells, 146
- Plant globins
evolutionary distance from mammalian, 70
- Plaque-forming cell responses
and suppressor T-cell subsets, 130
see also PFC
- Plasma glucose
table of islet transplantation, 192
- PNA
and IgE binding factor, 167
- Pneumonia
type III
response to sulphonamides, 4
- Polyarthritis
and collagen immunization, 200

- Polyclonal antibodies
 and antigenic structure of
 lysozyme, 77
 protein conformation, 94
 Polyclonal antisera
 quantitative micro-complement
 fixation technique, 90
 Polyene antibiotics
 lipid composition in, 268
 Polyenoic fatty acids
 and neutrophils, 271
 Polymorphonuclear leukocytes
 and chemoattractant receptors,
 276
 Polypeptide
 chain
 and immunoglobulin, 239
 use of
 synthetic made up of L-/D-
 AMINO ACIDS, 399-400
 Polysaccharides
 inhibition of anti-hapten re-
 sponses, 13-14
 and serum resistance, 482-83
 Poly-X haptens
 and monoclonal antibodies,
 112
 Precursor accumulation
 deletion of A and B determi-
 nants, 116
 Procarbazine hydrochloride
 and fetal allografts, 191-92
 Prophylactic vaccines
 early history, 5
 Prostaglandins
 and AAOP, 335
 generation of C3b, 303
 and macrophage activation,
 287
 synthesis
 and antipyretic drugs,
 341
 and suppressor cells,
 223
 Proteases
 neutral
 and macrophage activation,
 299
 Protein kinase C
 and transduction of chemoat-
 tractant signals, 259,
 275-76
 Proteins
 antigenic structure of; a reap-
 praisal
 conclusions, 94-95
 cytochrome, 80-85
 introduction, 67-69
 lysozyme, 75-80
 multideterminant-regulatory
 model, 89-94
 myoglobin, 69-75
 serum albumin, 85-88
 C-reactive
 effects of on complement
 activation by bacteria,
 473-74
 cross reacting, 91
 crypticity of, 119
 eosinophil-associated, 429-42
 membrane
 antigenicity of, 121
 Protein synthesis
 and hyperalgesia, 340-41
 and lymphocyte-derived che-
 motactic factor (LDCF),
 272
 Proteolysis
 Ti molecules
 presence of unique pep-
 tides, 45
 Protoplast fusion
 and cell transfection, 243-44
 Psoriasis
 and AAOP, 348
 Pyrogen
 and IL-2, 341
 R
 Radiation
 and release of histamine, 339
 Reactive oxygen intermediates
 see ROI
 Regulatory cell
 model
 and suppressor cells, 232
 Renal failure
 and diabetes, 183
 Rheumatic disease
 collagen autoimmunity, 211
 and MHC, 199
 Rheumatoid arthritis
 histologic changes in, 201
 role of lymphocytes, 349
 RNA
 S1 analysis, 241
 transfection of immunoglobulin,
 241, 246
 ROI
 and tumor cytotoxicity, 308
 S
 Serotonin
 and release of histamine, 339
 Serum albumin
 antigenic structure of, 85-88
 cross-reactive studies, 87
 repeating determinant hypo-
 thesis, 88
 suppressor cells, 225
 Signal molecules
 and functions of macrophage,
 310
 Siliac acid residues
 and Ti clones, 43
 Silica
 intravenous injections
 and islet allografts, 186
 Skin grafts
 allogenic, 16
 Somatostatin
 and islet isografts, 184
 Splenocytes
 and collagen arthritis, 207
 Stilbestrol
 early investigations, 2
 Streptococcus
 and relation to rheumatoid
 arthritis, 4
 Streptomycin
 early controls for, 5
 Streptozotocin
 and islet isografts, 184
 Superoxide anion generation
 and chemotaxis, 269
 Suppressor cells
 in the neonatal spleen, 222
 and TLI, 226
 Suppressor cells and im-
 munoregulation
 additional cells of the suppres-
 sor cascade, 146-47
 features shared among differ-
 ent systems, 116
 Igh V restrictions and molecu-
 lar organization of
 TsF, 147-49
 introduction, 127
 summary, 149-50
 suppressor T-cell subsets,
 130-32
 Ts₁ cells and factors, 133-35
 Ts₁ induction, 132-33
 Ts₂ cells and factors, 135-38
 Ts₃ cells and factors, 138-46
 SV40 promoter
 and immunoglobulin mole-
 cules, 245
 Synovial hyperplasia
 and collagen-induced arthritis,
 201
 Synovitis
 and collagen immune com-
 plexes, 204
 T
 T cells
 as activators, 55-56
 antigens, 35-36
 B cell cooperation, 16
 BSA responses, 86
 clonal expansion, 327
 clones
 and antibodies, 52
 and myoglobin, 75

- determinants in natural proteins presented to, 396-99
- DNP-reactive, 13
- function
- clonotypic surface structures in, 33-34
- human cytotoxic, 52
- hybridomas
- antisera to, 52
 - DNP Myc-primed, 172
 - and IgE-binding factor, 167
- and IL-2, 53
- interaction
- and IL-2, 325-26
 - and isotype-specific IgE regulation, 169
- lineage, 381-82
- lymphoid irradiation, 225
- lymphomas, 19
- malignancies, 329
- membrane
- and Ti and T3, 34
- MHC-restricted
- antigen receptor on, 51
 - and leukemia, 60
- mitosis, 320
- critical determinants, 331-32
- phenotype
- and tumor specific cells, 36
- proliferation
- and IL-2, 319
- response to collagen, 210
- response to cytochrome c polymer, 83
- suppressor systems
- see Suppressor cells and immunoregulation
- target
- and antireceptor antibodies, 54
- Thrombin receptor
- on platelets, 273
- Thymidine kinase gene
- from herpes simplex, 241
- Thymocytes
- and T-cell leukemia, 62-63
 - TL surface antigens, 228
- Thymoma
- transfectants
 - and kappa light chains, 249
- Thymus
- role of in immunity, 15-16
- Thyroid
- allografts, 189
- Thyroxine
- first synthesizer of, 2
- Ti
- clonotype
 - and 90KD disulfide-linked heterodimer, 41
 - molecules
 - SDS-page of (figure), 42
- T lymphocytes
- and antigen recognition, 45
 - clonal populations of, 23
 - and suppressor T cells, 130
 - and T dependent antigens, 127
 - see also Human T-cell receptor
- T-lymphocytotropic hormones
- see Interleukin 2
- T3 molecular complex
- and antibodies, 30
 - and effector cells, 37
- TNP
- antibodies specific for, 246
- Tolerance induction
- total lymphoid irradiation (TLI), 224
- Total lymphoid irradiation (TLI), 224
- Toxoplasma
- and macrophage, 309
- Transferrin
- receptor for
 - and macrophage, 296
- Transient expression
- and transfection of immunoglobulins, 240
- Transmethylation reactions
- and chemoattractants, 259
- chemoattractant receptors, 277
- Transmission electron microscopy
- and collagen induced arthritis, 202
- Trypanosomes
- and macrophage activation, 309
- Trypsin
- and binding
 - in macrophage activation, 305
 - and GEF, 175
 - and peptide-map comparisons, 45
- Tryptophan
- and eosinophil functions, 431
- Ts, induction
- and suppressor-cell interactions, 132-33
- T (Thomsen-Friedenreich) antigen
- and glycoproteins, 114-15
- Tumor cells
- binding site for, 296
 - and cytotoxic T-lymphocyte clones, 36-37
 - and NK cell heterogeneity, 374
- T cell
- peptide maps, 61
- Tumor cytolysis
- and macrophage functions, 303
- Tumors
- biochemical features of carbohydrate changes in, 104
- U
- Unit antigenic determinant
- and structure of proteins, 89
- Urea-denatured antigen
- and PEG conjugates, 161
- V
- Vacuolar system
- and macrophage capacity, 289
- Vascular permeability
- and AAOP, 336, 342-45
- Vasculitis
- and collagen-induced arthritis, 201
- Vesicular Stomatitis Virus (VSV)
- and tumor specific antigens, 109
- Viral mutations
- and antibody binding, 93
- X
- Xenografts
- and rejection of islet allografts, 183, 193-94
- X haptens
- and monoclonal antibodies, 112

